InflaRx NV expected to post a loss of 14 cents a share - Earnings Preview

InflaRx (IFRX) plans two Phase 2 trials for izicopan in ANCA-associated vasculitis, starting in 2027. The trials will involve 35 patients per arm and focus on renal involvement and glucocorticoid replacement. The company has €153.3M in cash, expected to fund operations through 2029. Izicopan has shown no safety concerns in 197 human subjects. Additional trials in IgA nephropathy and a Phase 3 trial in China are also planned.

InflaRx reported preclinical data showing izicopan reduced kidney injury in hamster models, supporting its development for renal diseases and AAV. The results demonstrate efficacy and PK/PD differentiation, according to the company.

InflaRx N.V. (IFRX) presented pre-clinical data showing its drug izicopan reduced kidney injury in two animal models. The study demonstrated izicopan's potential for treating complement-driven kidney diseases, with significant improvements in renal function markers and histopathological scores. The company plans to develop izicopan for ANCA-associated vasculitis and additional renal indications.

InflaRx N.V. (IFRX) will present pre-clinical data on its drug izicopan at Kidney Week 2026. Izicopan, an oral C5a receptor antagonist, showed promising results in kidney disease models and other inflammatory conditions. The company plans to develop izicopan for ANCA-associated vasculitis and renal diseases, highlighting its potential as a best-in-class treatment.

InflaRx N.V. (IFRX) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones • Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned • Initiated feasibility ass

Barclays kept Ethos Technologies at Overweight, raising its price target to $44 from $37, an 18.9% increase. This implies a 3.2% upside from the Nov 2 close of $42.62.